Research programme: limbal stem cell corneal implants - CIBER-BBN/Ferrer

Drug Profile

Research programme: limbal stem cell corneal implants - CIBER-BBN/Ferrer

Alternative Names: BIOSCAFF-EYE; BioSCniche; EYE-SCAFF; FIB-112; Ocular surface reconstruction therapeutics - CIBER-BBN/Ferrer

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator CIBER-BBN
  • Developer CIBER-BBN; Ferrer
  • Class Biopolymers; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Corneal disorders; Limbal stem cell deficiency

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Limbal-stem-cell-deficiency in Spain (Ophthalmic)
  • 16 Jul 2016 No recent reports of development identified for research development in Corneal-disorders in Spain (Ophthalmic)
  • 31 Oct 2012 Preclinical trials in Limbal stem cell deficiency in Spain (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top